RxDoctor Payments Data

Gregory Roberts, MD

Cardiovascular Disease · Wilmington, NCNPI 1023224839

Payments from drug & device makers

$5,011in general payments, 2019–2025

Across 295 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$870
  • E.r. Squibb & Sons, L.L.C.$811
  • Johnson & Johnson$568
  • Philips North America LLC$431
  • Boehringer Ingelheim$343
  • Merck$291
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,97199%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,011 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$373,190
Medicare patients
1,557
Services billed
5,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$468,054
XareltoRivaroxaban306$293,145
Repatha SureclickEvolocumab86$83,007
FarxigaDapagliflozin Propanediol103$80,870
EntrestoSacubitril/Valsartan43$41,240
Praluent PenAlirocumab34$20,438
Repatha SyringeEvolocumab19$16,332
VascepaIcosapent Ethyl31$11,535
JardianceEmpagliflozin14$11,186
Metoprolol Succinate746$11,185
MultaqDronedarone Hcl11$10,359
BrilintaTicagrelor15$7,588
Atorvastatin Calcium637$7,065
Rosuvastatin Calcium301$4,174
Diltiazem 24hr Er (Cd)Diltiazem Hcl82$4,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$261$468,054437 claims
Johnson & JohnsonXarelto$568$293,145306 claims
AstraZenecaFarxiga, Brilinta$177$88,458118 claims
NovartisEntresto$870$41,24043 claims
Boehringer IngelheimJardiance$343$11,18614 claims
Sanofi-aventis U.S. LLCMultaq$276$10,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →